Pfizer drops its B7-H4 conjugate
Felmetatug vedotin’s exit could be bad news for Mersana.
Cargo can't replicate firi-cel's academic success
Firce-1 is scrapped after showing dismal response rates and patient deaths.
Zentalis doubles down on Wee1
But the new focus on a predictive biomarker could cut the market in half.
A Leap into the subgroups
On a wing and a prayer Leap heads for phase 3.
ASCO-GI – a second colorectal win for Bristol's combo
Opdivo and Yervoy succeed again, but the US path remains unclear.
